Philadelphia Antitrust Litigation Lawyers
Antitrust laws were enacted to protect U.S. consumers and businesses from
anti-competitive and monopolistic conduct that threatens our free and
open markets, the foundation of a vibrant economy. Increasingly, pharmaceutical
companies use patent litigation, and collusive settlements, to disrupt
fair and open competition, particularly by delaying the market entry of
cheaper generic drugs, the availability of which Congress has set as a
priority since at least the enactment of the Hatch-Waxman Act in 1984.
Pay-For-Delay & Reverse Payment Settlements
Blockbuster branded drug manufacturers all too often attempt to unlawfully
extend their exclusivity in the marketplace by suing generic drug manufacturers
who seek to bring cheaper generic drugs into the market. “Reverse
payments” refers to unlawful settlements in which the brand company
pays the generic challenger -whether in monetary or non-monetary form
- to delay entry of a generic into the market. Such settlements make no
economic sense except as a form of unlawful payment not to compete. Since
the U.S. Supreme Court’s ruling in
FTC v. Actavis in 2013, such settlements can violate the antitrust laws, and injured
purchasers can now recover the ill-gotten gains of such conduct.
Leading Consumer Class Action Lawyers
Golomb & Honik, P.C. has recovered over $2 billion in settlements and
verdicts for our clients in both class action and individual litigation.
We are not afraid to take on the nations largest corporations and have
done so for decades. With our proven track record and dedicated team of
experienced attorneys, you can be sure that your case will receive the
tenacious representation that it deserves.
We are proud to provide all of our prospective clients with a complimentary
case consultation so that we can discuss how we may be able to assist you.
If you think you may have a case, contact our Philadelphia law firm today
at (215) 278-4449.